Pros | ![]() Beats FD returns for both 3Y & 5Y duration. | ![]() 5Y returns in the top 25% of the category. ![]() 3Y returns in the top 25% of the category. ![]() Among most bought funds within the category. | ||
Cons | - | - |
INDMoney rank | 4/8 | 3/8 | ||
Category,Subcateogry | Equity,Sector - Healthcare | Equity,Sector - Healthcare | ||
Fund Age | 6 Years | 7 Years | ||
Fund Size | 3107 Cr | 6162 Cr | ||
Min Investment | SIP ₹100 Lumpsum ₹100 | SIP ₹100 Lumpsum ₹5000 | ||
Expense Ratio | 0.6% | 1.04% | ||
Exit Load | 0.5% | 1% | ||
Benchmark Index | BSE Healthcare TR INR | BSE Healthcare TR INR |
No of Holdings | 32 | 40 | ||
Top 5 Holdings | Cipla Ltd (9.16%) Sun Pharmaceuticals Industries Ltd (7.88%) Ipca Laboratories Ltd (7.56%) Cohance Lifesciences Ltd (7.38%) Laurus Labs Ltd (6.12%) | Sun Pharmaceuticals Industries Ltd (11.71%) Dr Reddy's Laboratories Ltd (9.47%) Divi's Laboratories Ltd (9.23%) Cipla Ltd (7.39%) Aurobindo Pharma Ltd (6.53%) | ||
No of Sectors | 2 | 3 | ||
Top 3 Sectors | Health (98.53%) Financial Services (1.47%) | Health (97.35%) Basic Materials (1.5%) Financial Services (1.15%) | ||
Equity % | 97.14% | 95.88% | ||
Debt % | - | - | ||
P/E | 34.52 | 31.02 | ||
P/B | 5.13 | 4.22 | ||
Credit Quality | - | - | ||
Modified Duration | - | - | ||
YTM | - | - |
1-Month Return | -1.33% | 0.6% | ||
3-Month Return | -1.05% | 2.06% | ||
6-Month Return | 10.85% | 17.65% | ||
1-Year Return | -4.29% | 4.93% | ||
3-Year Return | 24% | 29.02% | ||
5-Year Return | 18.53% | 21.08% |
Sharpe | 1.1 | 1.24 | ||
Alpha | 2.77 | 4.3 | ||
Beta | 0.84 | 0.95 | ||
Standard Deviation | 14.69 | 15.67 | ||
Information Ratio | 0.1 | 1.4 |
Description | DSP Healthcare Fund Direct Growth is an equity fund.The fund could potentially beat inflation in the long-run. | ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund Direct Growth is an equity fund.The fund could potentially beat inflation in the long-run. | ||
Managers | Chirag Dagli | Dharmesh Kakkad,Sharmila D’mello |